Alterity Therapeutics (NASDAQ:ATHE) Now Covered by Analysts at Maxim Group

Maxim Group started coverage on shares of Alterity Therapeutics (NASDAQ:ATHE) in a research note released on Thursday, Marketbeat reports. The brokerage issued a buy rating and a $8.00 price target on the stock.

Alterity Therapeutics Stock Up 5.0 %

Shares of ATHE stock opened at $2.33 on Thursday. Alterity Therapeutics has a 52 week low of $1.00 and a 52 week high of $3.25. The firm’s 50-day simple moving average is $1.34 and its two-hundred day simple moving average is $1.50.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.